EUVIMEDEUVIMED entdecken
Crossref

Does the Combination of Anticoagulants and Angiogenesis Inhibitors Increase the Risk of Bleeding in Cancer Patients?

Erhöht die Kombination von Antikoagulanzien und Angiogeneseinhibitoren das Blutungsrisiko bei Krebspatient:innen?

Qixin Chen, Xiaoting Huang, Shen Lin, Shaohong Luo, Dongni Nian, Ningning Lin, Xiuhua Weng, Xiongwei Xu iD

Thrombosis and Haemostasis · 2026-11 · 126 (11) · 1143-1156

DOI: 10.1055/a-2740-1655 ↗

Auf einen Blick

Eine Netzwerk-Metaanalyse und eine Kohortenstudie prüften das Blutungsrisiko unter Angiogeneseinhibitoren mit oder ohne Antikoagulanzien. Unter hochdosiertem Bevacizumab und antiangiogenen Tyrosinkinaseinhibitoren war das Risiko höher.

Fragestellung

Erhöht die Kombination von Antikoagulanzien und Angiogeneseinhibitoren bei Krebspatient:innen das Blutungsrisiko?

Methode

Netzwerk-Metaanalyse auf Basis von PubMed, EMBASE und Cochrane Central Register of Controlled Trials; zusätzlich Real-World-Kohorte mit 645 Patient:innen von Januar 2010 bis Juni 2024.

Ergebnisse

2.644 Patient:innen aus 6 Studien; 614 (23,2 %) Blutungsereignisse. Zusatz von Antikoagulation: hochdosiertes Bevacizumab OR 4,95 (95 %-KI 2,68–9,42), antiangiogene TKIs OR 2,2 (95 %-KI 1,08–4,44); niedrige Bevacizumab-Dosen ohne solchen Effekt. In der Kohorte 28 (17,2 %) vs. 16 (9,8 %) Blutungen.

Schlussfolgerung der Autor:innen

Die Autor:innen folgern, dass die Zugabe von Antikoagulation zu hochdosiertem Bevacizumab oder antiangiogenen TKIs das Blutungsrisiko erhöhen könnte. Bei niedrig dosiertem Bevacizumab schienen Antikoagulanzien sicher zu sein.

Kernaussagen

  • 2.644 Patient:innen aus 6 Studien
  • Mehr Blutungen mit Antikoagulation bei hochdosiertem Bevacizumab und TKIs
  • Bei niedrig dosiertem Bevacizumab zeigte sich kein erhöhter Effekt

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 28.11.2025. Verfasst von Qixin Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Hemorrhage, Angiogenesis Inhibitors, Anticoagulants, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province, Medical Innovation Project of Fujian Province.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The advent of angiogenesis inhibitors has expanded therapeutic options for tumors but poses challenges due to bleeding risks, especially in patients requiring anticoagulation therapy for cancer-associated hypercoagulability. This study aimed to evaluate whether combining anticoagulants with angiogenesis inhibitors increases bleeding risk in cancer patients. A network meta-analysis was conducted based on PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials to compare bleeding risks with angiogenesis inhibitors alone versus their combination with anticoagulants. Furthermore, a real-world cohort of 645 patients receiving antiangiogenic therapies between January 2010 and June 2024 was studied. Patients were separated into two groups according to whether they were receiving concomitant anticoagulants. The primary outcome was all-grade bleeding events. Of 2,644 patients from six studies included in network meta-analysis, all-grade bleeding events were found in 614 (23.2%) patients. The addition of anticoagulation to either high-dose bevacizumab (10 or 15 mg/kg) (OR 4.95, 95% CI: 2.68–9.42) or antiangiogenic tyrosine kinase inhibitors (OR 2.2, 95% CI: 1.08–4.44) significantly increased bleeding risk compared with antiangiogenic monotherapy, except for low-dose bevacizumab (5 or 7.5 mg/kg). In the cohort study, 163 patients matched in each group after propensity score matching weighting. Over a median follow-up duration of 56 days, there were 28 (17.2%) all-grade bleeding events during concurrent treatment and 16 (9.8%) all-grade bleeding events reported during antiangiogenic monotherapy. Adding anticoagulation to high-dose bevacizumab or antiangiogenic TKIs might increase bleeding risk compared with monotherapy. Conversely, anticoagulants appeared to be safe in patients receiving low-dose bevacizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemorrhageAngiogenesis InhibitorsAnticoagulantsNeoplasmsHumansRisk FactorsBevacizumabFemaleDrug Therapy, CombinationMaleAgedMiddle Aged

Substanzen

Angiogenesis InhibitorsAnticoagulantsBevacizumab

Autor:innen und Institutionen

  • School of Pharmacy, Fujian Medical University, Fuzhou, China.
  • Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Changle, China.
  • Department of Pharmacy, Fuzhou Second Hospital, Fuzhou, Fujian, China.
  • Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.

ORCID-Profile: Xiongwei Xu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Fujian Province
  • Medical Innovation Project of Fujian Province
  • Joint Funds for the Innovation of Science and Technology, Fujian Province

Zitieren

APA

Chen, Q., Huang, X., Lin, S., Luo, S., Nian, D., Lin, N., Weng, X., & Xu, X. (2026). Does the Combination of Anticoagulants and Angiogenesis Inhibitors Increase the Risk of Bleeding in Cancer Patients?. Thrombosis and Haemostasis, 126(11), 1143-1156. https://doi.org/10.1055/a-2740-1655

Vancouver

Chen Q, Huang X, Lin S, Luo S, Nian D, Lin N, et al. Does the Combination of Anticoagulants and Angiogenesis Inhibitors Increase the Risk of Bleeding in Cancer Patients?. Thrombosis and Haemostasis. 2026;126(11):1143-1156. doi:10.1055/a-2740-1655

BibTeX
@article{Chen2026,
  author = {Chen, Qixin and Huang, Xiaoting and Lin, Shen and Luo, Shaohong and Nian, Dongni and Lin, Ningning and Weng, Xiuhua and Xu, Xiongwei},
  title = {Does the Combination of Anticoagulants and Angiogenesis Inhibitors Increase the Risk of Bleeding in Cancer Patients?},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  volume = {126},
  number = {11},
  pages = {1143--1156},
  doi = {10.1055/a-2740-1655}
}
Kostenlos starten →